7169-95-1

Basic information

• Product Name: 6-BROMO-2-METHYL[1,2,4]TRIAZOLO[1,5-A]PYRIDINE
• Synonyms: 6-BROMO-2-METHYL[1,2,4]TRIAZOLO[1,5-A]PYRIDINE;[1,2,4]Triazolo[1,5-a]pyridine, 6-broMo-2-Methyl-
• CAS NO: 7169-95-1
• Molecular Formula: C₇H₆BrN₃
• Molecular Weight: 212.04664
• Mol File: 7169-95-1.mol
• Article Data: 5

Chemical Properties

• Melting Point: 153-155℃
• Appearance: /
• Density: 1.76±0.1 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 2.23±0.30(Predicted)
• CAS DataBase Reference: 6-BROMO-2-METHYL[1,2,4]TRIAZOLO[1,5-A]PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-2-METHYL[1,2,4]TRIAZOLO[1,5-A]PYRIDINE(7169-95-1)
• EPA Substance Registry System: 6-BROMO-2-METHYL[1,2,4]TRIAZOLO[1,5-A]PYRIDINE(7169-95-1)

Safety Data

• Hazardous Substances Data: 7169-95-1(Hazardous Substances Data)

Usage

General Description

6-Bromo-2-Methyl[1,2,4]triazolo[1,5-a]pyridine is a specific kind of organic compound that belongs to the group of triazolopyridines, compounds containing a triazolopyridine moiety, which is a six-membered aromatic heterocycle made up of four carbon atoms, one nitrogen atom and a triazole ring. The exact molecular formula of this chemical is C6H5BrN4 and it is characterized by a molar mass of 223.04 g/mol. The '6-Bromo' element in the name denotes the presence of a bromine atom in the 6-position of the heterocyclic ring, while '-2-Methyl' shows that a methyl group is attached at the 2-position. 6-BROMO-2-METHYL[1,2,4]TRIAZOLO[1,5-A]PYRIDINE can be utilized in various fields such as pharmaceuticals or as intermediates in synthetic chemistry. As with all chemicals, handling of 6-Bromo-2-Methyl[1,2,4]triazolo[1,5-a]pyridine should be done wearing appropriate protective gear to prevent exposure.

Upstream product

• 1072-97-5 5-bromo-2-pyridylamine 
• 1202704-57-1 (1,2-diamino-5-bromopyridin-1-ium) 2,4,6-trimethylbenzenesulfonate 
• 108-24-7 acetic anhydride 
• 368-39-8 triethyloxonium fluoroborate 

Downstream Products

• 1236325-09-9 (S)-6-(2-hydroxy-2-methylpropyl)-6-isopropyl-3-((S)-1-(4-(2-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl)ethyl)-1,3-oxazinan-2-one 
• 1202701-51-6 C₁₉H₁₈FN₅O₃ 
• 7169-94-0 2-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-amine 

Relevant articles and documents

Substituted heteroaryl compounds and compositions and uses thereof (by machine translation)

The invention discloses substituted heteroaryl compounds and compositions thereof and their use. The compounds of formula (I) compound or type shown in (I) a compound represented by stereo isomers, tautomers, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt or its prodrug. The invention also provides a pharmaceutical composition, the compounds and pharmaceutical compositions can be regulated protein kinase, particularly Aurora kinase and JAK kinase activity, for the prevention, treatment, treatment and reduce protein kinase, in particular JAK kinase activity mediated diseases or disorders. (by machine translation)

OXAZOLIDINONE DERIVATIVE HAVING FUSED RING

The present invention provides a novel antimicrobial drug comprising an oxazolidinone derivative of the formula (I): or a pharmaceutically acceptable salt or solvate thereof; wherein ring A is ring B is a benzene ring optionally substituted with lower alkyl; ring C is an optionally substituted six-membered heterocycle containing at least one nitrogen atom and one to three double bond(s) in the ling wherein the atom at the point of attachment to ring B is a carbon atom; ring D is an optionally substituted five-membered ring containing one or two double bond(s) in the ring; A1 and A2 are independently nitrogen or carbon; m is 0 or 1; R represents H, —NHC(═O)RA, —NHC(═S)RA, —NH-het1, —O-het1, —S-het1, —S(═O)-het1, —S(═O)2-het1, het2, —CONHRA, —OH, lower alkyl, lower alkoxy or lower alkenyl; and het1 and het2 are independently a heterocyclic group; with the proviso that the fused ring C-D is not

(2S,3S)-3-amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1, 2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: A selective α-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

A series of β-substituted biarylphenylalanine amides were synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-4) for the treatment of type 2 diabetes. Optimization of the metabolic profile of early analogues led to the discovery of (2S